Novartis has struck a deal with Parvus Therapeutics -- a small, virtual biotech in Canada -- for exclusive rights to use Parvus' technology to develop and commercialize products for the treatment of type 1 diabetes.
Parvus has entered into a license and collaboration agreement with Novartis for its lead Navacim platform. According to Parvus, Navacims constitute a novel pharmacological class of therapeutic comprised of nanoparticles (NPs) coated with disease-relevant peptide-major histocompatibility complexes (pMHCs) that alter the behavior of disease-causing T lymphocytes.
Novartis will be will be responsible for clinical-stage development and commercialization activities. Parvus will be primarily responsible for conducting the ongoing preclinical work for the T1D program and filing the IND in collaboration with Novartis through a joint steering committee.
Read the press release